Fundraising Fox
/Companies
Sign in

Excepgen

YC W19

San Francisco, US · 3 employees · 16 known investors

Find your way into Excepgen

Sign up to see every warm intro you have to Excepgen

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Excepgen team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ExcepGen develops biologics, gene therapies, and vaccines using synthetic biology approaches to create therapies that operate outside normal cellular regulation constraints.

Also known as Excepgen INC

AI & Machine LearningBiotechHealthtechUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W19)

TFThomas Folliard
Thomas FolliardCo-Founder and CEOThomas Folliard founded ExcepGen, which develops biologics, gene therapies, and vaccines using synthetic biology. He has expertise in foundational engineering of biology and drug discovery.
BM
Barbara MertinsChief Scientific Officer

Investors · 16

Jude Gomilalisted by Jude GomilaLynnwood

How we know: Jude Gomila's portfolio page · Not right? Tell us

Oxonian Ventureslisted by Oxonian VenturesPalo Alto

How we know: the VCSheet dataset · Not right? Tell us

Pi Campuslisted by Pi CampusRome · $55K – $540K
Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

ZAKA VClisted by ZAKA VCSan Francisco
AJGreported

How we know: Y Combinator's founder network · Not right? Tell us

ECMC GroupreportedMinneapolis · $500K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

Emles Advisorsreported

How we know: Y Combinator's founder network · Not right? Tell us

Four CitiesreportedNewton

How we know: Y Combinator's founder network · Not right? Tell us

Oxford Angel FundreportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

Sam Altmanreported

How we know: Y Combinator's founder network · Not right? Tell us

SAP.iO Foundryreported

How we know: Y Combinator's founder network · Not right? Tell us

SNAK Venture PartnersreportedChicago

How we know: Y Combinator's founder network · Not right? Tell us

SV AngelreportedSan Francisco · $150K – $20M

How we know: Y Combinator's founder network · Not right? Tell us

Venture Investment AssociatesreportedPeapack

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 8

UnimaUnima makes portable diagnostic tests that deliver disease identification at the point of care within 15 minutes at low cost, enabling rapid detection and monitoring of infectious diseases.
Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Entelexo BiotherapeuticsEntelexo develops engineered exosome therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company uses a proprietary platform to design exosomes that communicate with multiple diseased cell types simultaneously, replacing traditional single-target treatments.
Macrogenics IncMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
IsablIsabl develops whole genome and transcriptome sequencing technology for cancer diagnosis, delivering comprehensive genomic profiling and treatment options to physicians and research teams. The company provides rapid cancer diagnostic tests in clinically relevant timeframes to improve outcomes for cancer patients globally.
Science ExchangeScience Exchange provides operational infrastructure for life sciences R&D, connecting organizations, suppliers, and workflows to streamline contracting, compliance, onboarding, and financial coordination across the research ecosystem.
InvitrisInvitris develops cell-free protein synthesis platforms that enable rapid design, expression, and scalable production of complex proteins for biopharmaceuticals, industrial biotechnology, and agriculture.
PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

Companies working in the same space as Excepgen.

Legal entities · 1

corporate structure
ExcepGen Inc

Frequently asked questions

What does Excepgen do?
ExcepGen develops biologics, gene therapies, and vaccines using synthetic biology approaches to create therapies that operate outside normal cellular regulation constraints.
Who founded Excepgen?
Excepgen was founded by Thomas Folliard.
Who are Excepgen's investors?
Excepgen's investors include Gravity, Jude Gomila, Oxonian Ventures, Pi Campus, Y Combinator, ZAKA VC, AJG, ECMC Group and 8 more.
Where is Excepgen headquartered?
Excepgen is headquartered in San Francisco, US.